- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe chronic plaque psoriasis. Severe psoriatic arthritis.
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Ustekinumab – March 2026
Injection 45 mg in 0.5 mL single use pre-filled syringe, Injection 90 mg in 1 mL single use pre-filled syringe
Last updated
11 March 2026